Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRV + bevacizumab versus bevacizumab maintenance in FRα-high platinum-sensitive recurrent ovarian cancer
MOH_2023-06-25_012748Phase 3Active, not recruiting
- Sponsor
- ImmunoGen
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Elahere + bevacizumab maintenance with Bevacizumab maintenance (2 arms). Started May 2023; status: active, not recruiting.
02
Drugs
mirvetuximab soravtansinebevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2023-06-25_012748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-25_012748.